A gene marker may help predict how thalamic brain tumors act
Original title: Clinical and molecular characteristics of thalamic gliomas in adults: prognostic impact of TERT promoter mutation.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a look back at past patient records, not a test of any treatment.
The short version
In 45 adults with brain tumors in the thalamus: A part deep in the brain, near its center. It passes messages from the senses and the body on to the rest of the brain. See the glossary, one gene change was tied to shorter survival.
What was studied. Doctors looked back at 45 adults who had surgery or a biopsy for a glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary in the thalamus: A part deep in the brain, near its center. It passes messages from the senses and the body on to the rest of the brain. See the glossary. The surgeries took place between 2007 and 2023, and the team checked tumor genes and survival.
What they found. People with a tumor type called diffuse midline glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary lived 24.6 months. People with glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary lived 12.4 months. A gene change called TERT promoter mutation: A change in the switch that controls the TERT gene. It keeps tumor cells from aging out. It is one of several findings your team reads together to name the tumor. See the glossary promoter was linked to a higher risk of dying. Another gene change, called H3K27M, was not linked to survival.
What this means, and what it doesn't
What it could mean: Testing for the TERT promoter mutation: A change in the switch that controls the TERT gene. It keeps tumor cells from aging out. It is one of several findings your team reads together to name the tumor. See the glossary promoter change may help doctors judge how a tumor is likely to act. That kind of information can help you and your care team plan ahead. The study also suggests these tumors do not all behave the same way.
What it doesn't mean: This is not a new treatment, and it is not a promise of more time. No drug was tested here. The doctors only looked back at records of past patients at one center. A marker that predicts risk is not the same as something that treats the tumor. It is also a small group of people, so the results may not hold true for everyone.
Source: PubMed, August 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.